<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04903301</url>
  </required_header>
  <id_info>
    <org_study_id>CV-LASIK</org_study_id>
    <nct_id>NCT04903301</nct_id>
  </id_info>
  <brief_title>Patient Satisfaction With Contoura Vision Topography-Guided LASIK</brief_title>
  <official_title>Patient Satisfaction With Contoura Vision Topography-Guided LASIK</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush Eye Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rush Eye Associates</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate patient reported outcomes associated with quality of vision before and after&#xD;
      treatment with Contoura Vision Topography-Guided LASIK.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2021</start_date>
  <completion_date type="Anticipated">May 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 21, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global Vision Satisfaction Index</measure>
    <time_frame>26 weeks</time_frame>
    <description>Analog Score from Adapted from PROWL Survey</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vision</measure>
    <time_frame>26 weeks</time_frame>
    <description>Uncorrected Visual Acuity using ETDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Scatter Index</measure>
    <time_frame>26 weeks</time_frame>
    <description>HD Analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Higher Order Corneal Aberrations</measure>
    <time_frame>26 weeks</time_frame>
    <description>Galilei Topography</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Myopia</condition>
  <condition>Astigmatism</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Contoura Vision LASIK using Phorcides Analytic Software</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Contoura Vision LASIK</intervention_name>
    <description>Topography-Guided LASIK using Phorcides Analytic Software</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility criteria: The study enrollment will include all willing patients with:&#xD;
        pre-operative BCVA 20/20 for each eye individually, myopic refractive error up to -8.00&#xD;
        diopters, refractive astigmatism that ranges from 0 to 3 diopters, maximum spherical&#xD;
        equivalent of -9.00 diopters, the designated age requirements, and only patients that have&#xD;
        signed the informed consent document.&#xD;
&#xD;
        Exclusion criteria: Patients are excluded that are not willing to participate in a research&#xD;
        trial, are unable to cooperate well enough to safely perform the procedure, fail to meet&#xD;
        inclusion criteria, have ocular disease (including but not limited to keratoconus, macular&#xD;
        degeneration, glaucoma, corneal dystrophy, dry eye syndrome and corneal scarring), and&#xD;
        patients that have had previous ocular surgery. Any patients with known allergies to the&#xD;
        post-operative medications or preservatives in the medications will also be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sloan Rush, MD</last_name>
    <phone>806-353-0125</phone>
    <email>sunday.fowler@paneye.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rush Eye Associates</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunday Fowler</last_name>
      <phone>806-353-0125</phone>
    </contact>
    <investigator>
      <last_name>Sloan W Rush, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 21, 2021</study_first_submitted>
  <study_first_submitted_qc>May 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rush Eye Associates</investigator_affiliation>
    <investigator_full_name>Sloan W. Rush, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Astigmatism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

